Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.18632/oncotarget.11179 http://scihub22266oqcxt.onion/10.18632/oncotarget.11179 C5308636!5308636!27517629     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Oncotarget 2016 ; 7 (38): 61069-80 Nephropedia Template TP {{tp|p=27517629|t=2016. Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia |pdf=|usr=}}{{27517629}} gab.com Text Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia JO: Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=27517629 #FOAvip Emerging studies suggest that dominant peripheral tolerance is a major mechanism of immune escape in disseminated leukemia. Using an established murine acute myeloid leukemia (AML) model, we here show that systemic administration of recombinant IL-33 dramatically inhibits the leukemia growth and prolongs the survival of leukemia-bearing mice in a CD8+ T cell dependent manner. Exogenous IL-33 treatment enhanced anti-leukemia activity by increasing the expansion and IFN-? production of leukemia-reactive CD8+ T cells. Moreover, IL-33 promoted dendritic cell (DC) maturation and activation in favor of its cross presentation ability to evoke a vigorous anti-leukemia immune response. Finally, we found that the combination of PD-1 blockade with IL-33 further prolonged the survival, with half of the mice achieving complete regression. Our data establish a role of exogenous IL-33 in reversing T cell tolerance, and suggest its potential clinical implication into leukemia immunotherapy. Twit Text FOAVip Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia ????Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=27517629 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27517629 #FOAvip English Wikipedia <ref>{{Cite pmid|27517629}}</ref> Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia #MMPMID27517629 Qin L; Dominguez D; Chen S; Fan J; Long A; Zhang M; Fang D; Zhang Y; Kuzel TM; Zhang B Oncotarget 2016[Sep]; 7 (38): 61069-80 PMID27517629show ga Emerging studies suggest that dominant peripheral tolerance is a major mechanism of immune escape in disseminated leukemia. Using an established murine acute myeloid leukemia (AML) model, we here show that systemic administration of recombinant IL-33 dramatically inhibits the leukemia growth and prolongs the survival of leukemia-bearing mice in a CD8+ T cell dependent manner. Exogenous IL-33 treatment enhanced anti-leukemia activity by increasing the expansion and IFN-? production of leukemia-reactive CD8+ T cells. Moreover, IL-33 promoted dendritic cell (DC) maturation and activation in favor of its cross presentation ability to evoke a vigorous anti-leukemia immune response. Finally, we found that the combination of PD-1 blockade with IL-33 further prolonged the survival, with half of the mice achieving complete regression. Our data establish a role of exogenous IL-33 in reversing T cell tolerance, and suggest its potential clinical implication into leukemia immunotherapy. äExogenous IL-33 overcomes T cell tolerance in murine acute myeloid leu(epmc).pdf DeepDyve Pubget Overpricing